Related Experiment Video
Updated: Aug 22, 2026

Simple and Fast Rolling Circle Amplification-Based Detection of Topoisomerase 1 Activity in Crude Biological Samples
Published on: December 2, 2022
Topoisomerase I interactive agents
P Kellie Turner1, Lisa C Iacono, Clinton F Stewart
1Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
Abstract:
Increased insight into the mechanism of interaction of topoisomerase I interactive agents will maximize the therapeutic index and enhance the development of additional agents. Preclinical studies designed to elucidate mechanisms by which the topoisomerase I interactive agents induce cell death will be essential. The role of ABC transporters in resistance to topoisomerase I interactive agents has been recently appreciated and future studies should be directed at circumventing this resistance. The results of preclinical studies must be translated into the design of clinical trials so that these agents can be used rationally. In this regard results of preclinical studies have clearly pointed to the enhanced antitumor activity from protracted dosing of topoisomerase I interactive agents and results of clinical trials are now supporting these preclinical findings. Finally, investigators are trying to understand better the mechanism(s) of the dose-limiting toxicities observed with the currently available topoisomerase I interactive agents in an effort to enable the optimal dosing of these agents. Even though the first priority must be to determine the therapeutic potential of the currently available agents, it is reassuring to know that other topoisomerase I interactive agents are currently under development.
Insights
Understanding topoisomerase I agents is key to improving cancer therapy. Research focuses on mechanisms, overcoming resistance, and optimizing dosing for better antitumor activity and reduced toxicity.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Topoisomerase I interactive agents are crucial in cancer therapy.
- Maximizing their therapeutic index requires deeper mechanistic insight.
Purpose of the Study:
- Elucidate mechanisms of cell death induced by topoisomerase I agents.
- Investigate and circumvent ABC transporter-mediated resistance.
- Optimize dosing strategies for enhanced antitumor activity and reduced toxicity.
Main Methods:
- Preclinical studies to understand drug-induced cell death.
- Research into the role of ABC transporters in drug resistance.
- Translational research linking preclinical findings to clinical trial design.
Main Results:
- Protracted dosing of topoisomerase I agents shows enhanced antitumor activity.
- Clinical trials are beginning to support preclinical dosing observations.
- Understanding dose-limiting toxicities is crucial for optimal agent use.
Conclusions:
- Further research into topoisomerase I agent mechanisms is essential.
- Overcoming drug resistance and optimizing dosing will improve therapeutic outcomes.
- Ongoing development of new topoisomerase I agents offers future therapeutic potential.
Related Concept Videos
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. Type I...
DNA Helicases
Inhibitors of Bacterial DNA Synthesis
Translesion DNA Polymerases
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
Ribozymes
Ribozymes can be...
Ribozymes
Ribozymes can be...

